TAM
MYGN icon

Third Avenue Management’s Myriad Genetics MYGN Stock Holding History

Third Avenue Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-328,314
Closed -$6.89M – 164
2013
Q4 		$6.89M Buy
+328,314
New +$8.3M 0.13% 110

Other funds holding MYGN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Tiger Global Management
Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Third Avenue Management's MYGN Position: Q1 2014 in Review

Third Avenue Management sold out of Myriad Genetics (MYGN) in Q1 2014, closing a stake of 328,314 shares — an estimated $6.89M sold.

Third Avenue Management first reported a position in MYGN in Q4 2013 and held it in 1 quarter. The position peaked at $6.89M in Q4 2013. 280 funds tracked by Wall St. Rank hold MYGN as of Q1 2014.

  • Third Avenue Management reported no remaining Myriad Genetics position as of Q1 2014 after selling out during the quarter.
  • Third Avenue Management sold 328,314 Myriad Genetics shares in Q1 2014, an estimated $6.89M.
  • Third Avenue Management first reported a position in Myriad Genetics in Q4 2013 and held it in 1 quarter.
  • Third Avenue Management's Myriad Genetics position peaked at $6.89M in Q4 2013.
  • 280 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2014.

Based on Third Avenue Management's 13F filing for Q1 2014, filed 14 May 2014.